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Abstract 
 
 
Mycobacteria from the Mycobacterium avium complex act as opportunistic 
pathogens and infect patients with a compromised immune system, namely those 
infected with HIV, with cancer or immunosuppressed for the purpose of organ 
transplant. In the host, mycobacteria proliferate inside phagocytic cells, such as 
macrophages. There, they control the intracellular vesicular trafficking by inhibiting the 
phagosome-lysosome fusion, which allows these bacteria to escape the lysosomal 
acidic environment and to have access to nutrients. 
Different strains of M. avium have different susceptibilities to conventional 
antibiotics used in the clinic. It is then important to understand their behavior when 
trying to find new solutions for the treatments, including the re-purposing of old drugs. 
Recently, ionic liquids (ILs) have gained much attention in the area of drug 
development, as they can potentially be used to overcome unfavorable properties of 
some drugs, like solubility or toxicity. Chloroquine (CQ) is an antimalarial drug, which 
was shown to have an inhibitory effect in the viability of M. avium, suggesting it can be 
of use to treat infections by this agent.  
The aim of this work was to evaluate the susceptibility of different M. avium 
laboratory strains to antibiotics currently used to treat non-tuberculous mycobacteria-
related diseases, and, afterwards, to test the capacity of CQ-based ILs to inhibit the 
viability and growth of M. avium in axenic cultures and inside macrophages.  
Our results indicate that M. avium 2447 SmT was susceptible to all the tested 
conventional antibiotics, in contrast to what happens with M. avium 25291 SmT, which 
seems to be resistant to the same antibiotics. The SmOp variant of M. avium 2-151 
was slightly more susceptible than the SmT variant of the same strain.  
ILs based on CQ-cinnamic acid conjugates were as effective against M. avium, 
extracellularly and inside macrophages, as its covalent equivalents. However, they 
were more soluble and less toxic for the host cells. The conjugation of CQ or 
primaquine (PQ) with fluoroquinolones, that are sometimes used to treat mycobacterial 
infections, resulted in ILs that have the same direct activity as the original antibiotics to 
M. avium, but are more active against the mycobacteria growing inside macrophages.  
In the future we aim to test new ILs based in first-line drugs against 
mycobacteria, conjugated with active molecules against other pathogens that can 
occur concomitantly with non-tuberculous mycobacterial infections. 
 
Keywords: antibiotics; chloroquine; ionic liquids; Mycobacterium avium. 
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Resumo 
 
As micobactérias que pertencem ao complexo Mycobacterium avium atuam 
como patogénios oportunistas que infetam pacientes com o sistema imune 
comprometido, nomeadamente doentes infetados com VIH, com cancro ou que foram 
sujeitos a transplante de órgão. No hospedeiro, as micobactérias proliferam 
preferencialmente dentro de células fagocíticas, como os macrófagos. No seu interior, 
controlam o tráfico intracelular de vesículas inibindo a fusão fagossoma-lisossoma, o 
que permite a estas bactérias escaparem ao ambiente acídico do lisossoma e terem 
acesso a nutrientes. 
Diferentes estirpes de M. avium têm diferentes suscetibilidades aos antibióticos 
usados convencionalmente na clínica. É, portanto, relevante perceber o seu 
comportamento quando se procuram novas soluções para os tratamentos atuais, 
incluindo o reposicionamento de fármacos previamente existentes. Recentemente, os 
líquidos iónicos (ILs) têm chamado muita atenção na área do desenvolvimento de 
novos fármacos, uma vez que têm o potencial de resolver problemas relacionados 
com a solubilidade e toxicidade de fármacos antigos. A cloroquina (CQ) é um fármaco 
anti-malárico que já demonstrou um efeito inibitório na viabilidade de M. avium, 
sugerindo que poderá ser útil para tratar infeções por este agente. 
O objetivo deste trabalho foi avaliar a suscetibilidade de diferentes estirpes 
laboratoriais de M. avium a antibióticos atualmente usados no tratamento de doenças 
causadas por micobactérias não-tuberculosas. De seguida, testar a capacidade de ILs 
baseados na CQ em inibir a viabilidade e crescimento de M. avium em culturas 
axénicas e dentro de macrófagos. 
Os resultados obtidos neste trabalho indicam que a estirpe M. avium 2447 SmT 
foi suscetível a todos os antibióticos testados, ao contrário da estirpe M. avium 25291 
SmT, que parece ser resistente contra os mesmos. Em relação à estirpe 2-151, a 
variante SmOp foi ligeiramente mais suscetível do que a variante SmT. 
Os ILs baseados em CQ conjugada com ácido cinâmico tiveram um efeito 
semelhante contra M. avium extracelular e intracelular aos seus equivalentes 
covalentes. No entanto, são mais solúveis e menos tóxicos para as células do 
hospedeiro. A conjugação da CQ ou da primaquina (PQ) com fluoroquinolonas, outra 
classe de antibióticos usados na clínica para tratar infeções causadas por 
micobactérias, resultou em ILs que têm a mesma atividade direta que os antibióticos 
originais, mas são mais ativos contra a micobactéria a crescer dentro de macrófagos.  
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No futuro pretendemos testar novos ILs baseados em fármacos de primeira-
linha contra micobactérias, conjugados com moléculas ativas contra outros patogénios 
que podem ocorrer concomitantemente com micobacterioses não-tuberculosas. 
 
Palavras-chave: antibióticos; cloroquina; líquidos iónicos; Mycobacterium avium. 
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Tuberculosis and NTM infection epidemiology  
 
According to the World Health Organization (WHO) [1], about one-quarter of the 
world’s population has latent tuberculosis (TB). In 2017, 10 million of those people fell 
ill with TB and 1.6 million died from it, including 230 000 children. Although it can affect 
any person from all age groups, external factors like smoking or concomitant conditions 
that impair the immune system, increase the susceptibility to TB. Actually, infection with 
the human immunodeficiency virus (HIV) raises about 20 to 30 times the predisposition 
of co-infection with Mycobacterium tuberculosis (Mtb). Although TB incidence is falling 
about 2% per year, the development of resistances to first-line antibiotics is delaying 
the WHO deadline to eradicate TB by 2030.  
The incidence of infections by nontuberculous mycobacteria (NTM) is 
increasing significantly worldwide, in particular caused by Mycobacterium avium 
complex (MAC) species. This complex includes two species with very similar medical 
characteristics, M. avium and M. intracellulare [2]. This type of mycobacteria act as 
opportunists and infect patients with a compromised immune system, namely patients 
who are infected with HIV, with cancer or who were subjected to a transplant [3-6]. The 
fact that NTM are widely-distributed organisms found in soil or water, with a highly 
hydrophobic cell wall, which facilitates its aerosolization, may explain its high-infectious 
behavior. Besides that, NTM are able to survive in harsh environments, such as 
chlorinated water, and they can adhere to surfaces and form biofilms, allowing them to 
persist in an environment for long periods of time [3, 4]. Their resistance to antibiotics 
is growing, which urges the finding of new alternative therapies to combat 
mycobacterial infections.   
Curiously, it has been reported that a local decline in TB incidence is 
coincidental with an increase in infections caused by NTM [6, 7]. There is not a single 
reason that justifies that phenomenon, but some explanations can be taken into 
account. For example, cases of cross-immunity between Mtb and NTM, in which each 
type of mycobacteria sensitizes the host to a second exposure of the other. Also, better 
public health conditions can be, in this case, a double-edge sword. While improved 
ventilation and plumbing was essential to reduce TB incidence, centralized water 
supply systems, disinfection of drinking water and the habit of showering instead of 
tub-bathing are associated with NTM colonization, leading to selection of these 
microorganisms due to their resistance to chlorination and higher exposure to 
mycobacteria through aerosolization. It must always be borne in mind that higher 
clinical awareness and better methods of diagnosis can explain an increased incidence 
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rate of NTM infections in the last years. However, every year studies are published 
worldwide reporting cases of NTM infection, mainly of patients fragilized by other lung-
associated diseases, like bronchiectasis, or with an immune system compromised by 
conditions like rheumatoid arthritis or HIV-infection.  
 
 
Mycobacterium avium 
 
Mycobacteria cell wall structure  
 
 Mycobacteria are Gram-positive, aerobic bacilli (Figure 2A) with a characteristic 
dense cell wall enriched in lipids (Figure 1). Mycolic acids, complex fatty acids of 60 to 
90 carbons, interact by esterification with arabinogalactan, a sugar polymer, forming an 
intermediate layer that confers high hydrophobicity and impermeability to several 
molecules, including antimicrobials [8, 9]. Below, a thick layer of peptidoglycan gives 
structural strength to the cell wall. The exterior layer of the wall is composed of 
glycolipids and lipoglycans that interact with the mycolic acids, which is covered by 
loose proteins, lipids and glycans [9]. All these lipid layers make mycobacteria acid-
fast, so they are not stained by the Gram method, instead they require a harsh 
procedure like the Ziehl-Neelsen staining [8].  
 
 
Figure 1 – Bacterial cell walls. Comparison between cell envelopes of mycobacteria and other bacteria (from [9]). 
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M. avium infection 
 
Mycobacteria enter the body either by the respiratory or gastrointestinal tracts. 
The latter is more common in AIDS patients, the former is frequent in people with pre-
existing pulmonary diseases [8, 10]. Among the more than 200 species of NTM known, 
MAC species are the mycobacteria most often isolated from respiratory samples of 
patients with lung disease, and from the four subspecies of MAC, M. avium subspecies 
hominissuis is the main responsible for the disease in humans [11-13]. The other 
subspecies of MAC are associated and have been isolated from cattle and poultry. 
The analysis of MAC isolates allows the identification of several strains. The 
virulence of the different strains is highly variable and can be related to the origin of the 
isolate or by the morphotypic variant of each strain. Three variants of MAC, based on 
colony morphology, have been described: smooth-transparent (SmT), smooth-opaque 
(SmOp) and rough (Rg). The SmT variants are usually characterized for being highly 
virulent, while the SmOp variant are often not virulent. The virulence of the Rg variants 
is very variable. Isolates from animals are generally more virulent than human isolates, 
and isolates from the environment are usually not able to infect mice [14]. The M. 
avium avium strain ATCC 25291, isolated in the 1960s from a chicken, is a SmT 
variant. It is used worldwide as a reference strain and is one of the strains with the 
highest virulence described so far. The strain 2447, isolated in the 1980s from an AIDS 
patient in Belgium, is also a SmT variant. When compared with other strains, it is of 
intermediate virulence. The strain 2-151 was also isolated from an AIDS patient, but in 
the US. From that isolate, SmT and SmOp variants were cloned. The latter forms 
dome-shaped, opaque colonies on solid medium and is less virulent than the SmT 
variant [14]. 
Mycobacteria infect many types of cells, but their main and most studied host is 
the macrophage. When M. avium infects murine bone-marrow derived macrophages 
(BMM), it localizes in tight, individual vacuoles in the cell (Figure 2B), where the 
mycobacteria exponentially grow, multiplying about six fold in seven days [15]. It was 
also observed that the vacuole divides, accompanying the multiplication of the 
mycobacteria in order to maintain it in tight vacuoles. This strategy allows the 
mycobacteria to better control the fusion of their vacuoles with others present in the 
cell, like lysosomes. The arrest of maturation of early mycobacterium-containing 
phagosomes to phagolysosomes is a well-known protective mechanism of this kind of 
bacteria [15]. That maturation arrest is possible due to recruitment to the phagosome 
membrane of proteins and phosphoinositides required to intracellular trafficking. This 
mechanism prevents the exposure of the mycobacteria to the lysosome acidic 
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environment, hydrolytic enzymes and macrophage antigen-presenting organelles [9]. 
Besides that, this mechanism facilitates the access of mycobacteria to nutrients, like 
iron, located in cell membrane-derived vesicles with which the early mycobacterium-
containing phagosomes are able to interact [15, 16]. 
 
 
Figure 2 – Mycobacterium avium. (A) Scanning electron microscopy (SEM) image of M. avium. Scale: 1 µm (from 
[17]). (B) Electron micrograph of murine BMM infected with M. avium (M). The bacterium is contained in tight vacuoles 
(double arrows) (from [15]).  
 
 
Control of M. avium growth by macrophages 
 
 When infected, the macrophage may inhibit the bacterial growth by 
mechanisms that involve oxidative damage. However, the production by the 
macrophage of nitric oxide [18], hydrogen peroxide [19] or superoxide [20] is not able 
to cause bacteriostasis or kill M. avium, while M. tuberculosis is not so resistant to 
these mechanisms. This can be explained by the ubiquitous presence of M. avium in 
environments, as water, that in certain conditions are enriched in oxygen and nitrogen 
reactive species, allowing these mycobacteria to develop resistance [16]. That does 
not happen to M. tuberculosis, as it can only survive inside mammalian hosts.  
 Thus, macrophages must have oxygen and nitrogen reactive species-
independent mechanisms that can control and eliminate M. avium [20]. An immune 
response centered in CD4+ T cells that produce IFN-g plays an important role in 
controlling this kind of infection. The depletion of IFN-g or of cytokines as IL-12 and IL-
18 that promote the maturation of naïve CD4+ T cells into IFN-g-producing Th1 cells, 
exacerbates M. avium infection [16, 21]. TNF also induces anti-M. avium activity in 
vitro, and in vivo is involved in maintaining the structure and integrity of granulomas. A 
deregulation in TNF signaling is related to apoptosis of the cells of the granulomas [16]. 
BA
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 Another way of restricting the growth of intracellular M. avium is by depriving 
the bacteria of nutrients essential for their survival. Signaling by cytokines such as IFN-
g can prevent the interaction of the M. avium-containing phagosomes with endosomes 
that carry nutrients [16, 22]. Playing an important role in the bacteriostasis of this type 
of mycobacteria are ion transporters present in the membrane of the infected 
phagosomes, such as NRAMP1, that pumps iron and other cations out, depriving the 
mycobacteria from it [20]. Also, enzymes that degrade important phagosome 
molecules and compounds that sequester other molecules, as is the case of iron 
chelators [22], are essential as well. 
 Macrophages undergo apoptosis as a mechanism to control the progression of 
infection. However, it was shown that some mycobacteria from MAC are able to 
escape the apoptotic bodies to the extra-cellular space, where they are phagocytized 
by healthy macrophages, infecting them [23]. 
 
 
NTM-related diseases and current treatments 
 
Diseases caused by MAC infection 
 
 When a person is infected with Mycobacterium tuberculosis (Mtb), the 
preferable site for location of the bacteria is the lung. A patient with pulmonary 
tuberculosis exhibits symptoms such as chronic cough, sputum production, appetite 
and weight loss, fever, night sweats and hemoptysis [24]. Some of these clinical 
features are very similar to the ones caused by a NTM infection. It is then 
comprehensible that the first treatments used to combat this kind of infection were 
antituberculous drugs, which were successful in some cases but demonstrated lower 
activity than against Mtb [25]. However, with the dissemination of NTM infections, 
mainly of MAC species, and the emergence of AIDS, a new strategy had to be 
followed. 
Besides lung disease, MAC infection can affect other regions of the body. 
Among the NTM, MAC is the main responsible for infections on the central nervous 
system (CNS) in patients either infected or non-infected with HIV, with mortality 
rounding the 80% of the cases [11]. The enlargement of one or more lymph nodes due 
to infection, lymphadenitis, is the most common NTM-associated disease in 
immunocompetent children between 1 and 5 years old [11, 26]. With clinical signs very 
similar to the ones presented by Mtb infection, lymphadenitis caused by slow growing 
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mycobacteria, mainly MAC, can persist for a long period of time even with a macrolide-
based therapy regimen. Other diseases caused by NTM have also been described 
either in immunosuppressed or immunocompetent patients, as is the case of chronic 
osteomyelitis, arthritis, endobronchial disease and peritonitis [26].  
 
 
Conventional antibiotics used against MAC infection  
 
The discovery of antibiotics that have a better effect against MAC than the 
antituberculous drugs previously used, revolutionized the treatment of MAC lung 
disease. The treatment basis of slow-growing NTM, in which MAC is included, is a 
macrolide. Clarithromycin or azithromycin (Table 1) are the usual options, having no 
significant differences in response between the two [12], although, as clarithromycin 
has been more extensively studied, it is the preferable choice. Azithromycin is, 
however, often administered in order to prevent drug interaction, as clarithromycin 
works both as substrate and inhibitor of cytochrome P 3A enzymes [27]. Macrolides 
inhibit protein synthesis by binding to the 50S ribosomal subunit in bacteria and 
preventing the elongation of the nascent peptide chain [27, 28]. These antibiotics have 
the best correlation between in vitro susceptibility results and clinical (in vivo) response 
[11, 25]. The innate drug resistance of NTM to the antimicrobial agents influences the 
in vivo response in a way that often cannot be predicted by in vitro susceptibility 
results, such as minimum inhibitory concentration (MIC). These differences were 
observed in several species of rapid growth mycobacteria, such as M. abscessus, as 
well as in Mtb, and are related to the inducible macrolide resistance gene or erm gene. 
The activation of this gene reduces the binding of macrolides to the ribosome by 
methylation of an adenine in the 23S rRNA [11, 12, 27-29].  
A regimen of monotherapy with macrolides is, thus, very dangerous as it will 
often lead to drug resistance and consequent treatment failure associated with 
increased levels of mortality. So, a three-drug macrolide-based regimen with 
ethambutol and a rifamycin, is the MAC recommended treatment, with favorable 
microbiologic results and avoidance of antibiotic resistances [12, 27, 29]. Ethambutol 
interferes with the mycobacterial cell wall synthesis by inhibition of arabinosyl 
transferases, which affects the synthesis of arabinogalactan (AG) and 
lipoarabinomannan (LAM). Its ability to alter the permeability of the cell wall, allowing 
the passage of other antimycobacterial drugs, is its major advantage. Besides that, 
there are no known drug interactions with ethambutol. This antibiotic has a favorable 
activity against slow growth mycobacteria, including MAC, but high levels of resistance 
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against rapid growth species excludes its use in the treatment of this type of bacterial 
infection [11, 27, 28]. Rifamycins like rifampicin (Table 1) and rifabutin complement the 
treatment. They bind and inhibit DNA-dependent RNA polymerases, interrupting 
protein synthesis early on the transcription process. Co-infection with HIV may 
decrease the absorption of rifamycins, and particularly rifampicin is known to reduce 
the concentrations of several antiretroviral drugs. Mtb has acquired resistance to this 
antimycobacterial agent due to mutations on the gene that encodes RNA polymerase 
b-subunit. Rifamycins are involved in multiple interactions with other drugs, and studies 
with patients infected with NTM show low tolerance to rifabutin, although it has better in 
vitro and in vivo activity against MAC than rifampicin [11, 12, 27, 28]. From the three 
types of drugs recommended to treat MAC infections, rifamycins contribute the most to 
suboptimal pharmacokinetics (PK) and pharmacodynamics (PD) parameters. In fact, 
poor antimycobacterial activities and several interactions with other agents, resulting in 
the reduction of the plasma concentration of these drugs, require the increase of the 
dosages to levels that become intolerable to the patients [12, 29].  
 
 
New developments and challenges in the treatment of MAC infection 
 
The addition of a fourth drug to the regimen, like the aminoglycosides amikacin 
or streptomycin (Table 1), can be important in specific cases, like severe disseminated 
MAC disease in patients with AIDS, and is essential in cases of macrolide-resistant 
MAC. Low tolerance to rifamycins can be overcome with clofazimine combined with a 
macrolide and ethambutol, however its use was related to an increase in mortality of 
HIV co-infected patients. Fluoroquinolones, like norfloxacin and ofloxacin (Table 1), 
have been included in the therapy of lung disease caused by macrolide-resistant MAC, 
however their use as first-line drugs is inadvisable as well as in a 
macrolide/fluoroquinolone regimen, in order to minimize drug resistance  [11, 12, 27, 
29, 30]. Therefore, new drugs with improved pharmacological indices are 
indispensable to maximize the success of the treatments and improve the life of the 
patients. Amikacin liposome inhalation suspension (ALIS) and bedaquiline are the two 
new promises, the former is still in phase III trials but phase II tests were encouraging, 
and the latter is very effective against drug-resistance tuberculosis [12]. 
At the core of the unsuccess of the MAC infection treatments is also the lack of 
adherence by the health professionals to the established guidelines [12, 29, 31]. That 
is, actually, one of the greatest issues behind the threat that is the resistance to 
antibiotics nowadays. The prescription of a multi-drug therapy is the cornerstone to 
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avoid macrolide resistance and to prevent unnecessary deaths, since surgical lung 
resection is many times the only solution for patients who fail drug therapy by 
developing antibiotic resistances [11]. Cases of re-infection with MAC after or during 
therapy are also a concern, affecting mainly patients with a severely 
immunocompromised system [25]. On the other hand, as the drugs utilized for MAC 
infection frequently have high toxicity, not compensated by high efficacy against MAC, 
health professionals sometimes opt for no treatment. Instead, the less severe cases 
are kept under clinical observation. 
 
 
Alternative approaches to treat bacterial infections 
 
The role of chloroquine in the viability of M. avium 
 
Chloroquine (CQ) (Figure 3) was first synthetized during World War II, in 
consequence of a series of tests regarding the antimalarial potential of 4-
aminoquinolines, in which CQ showed to be the most promising drug, due to its good 
efficacy, low toxicity, tolerable adverse effects and affordability [32-34]. Besides 
malaria, CQ and its analogues are also used as secondary drugs in the treatment of 
chronic diseases, like rheumatoid arthritis, lupus or sarcoidosis [32]. It was 
demonstrated that CQ has anti-HIV-1 activity in vitro, but also that it has anti-
inflammatory properties, as it reduces the secretion of several pro-inflammatory 
cytokines. Furthermore, it was shown that CQ has an inhibitory effect in the viability of 
M. avium in mouse cells [35]. All these properties together suggested an urge in 
exploring CQ as a multi-versed drug in the treatment of AIDS-related opportunistic 
infections. 
 
 
 
 
 
 
 
 
Figure 3 – Chloroquine. Chemical structure of chloroquine (adapted from: [36]). 
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Past experiments in our laboratory showed that CQ has a significant inhibitory 
effect in vitro against the axenic growth of M. avium and even when the bacteria are 
growing inside bone marrow derived macrophages (BMM). That inhibitory effect was 
also demonstrated in vivo: BALB/c and C.D 2 mice infected with M. avium 2447 SmT 
treated with 30 mg/kg of CQ every other day showed a significant decrease of bacterial 
loads in the liver (unpublished data).  
In a more recent work, which tested the effect of CQ in a gram-positive bacteria, 
Rhodococcus equi, that, similarly to M. avium, infects preferentially macrophages, it 
was shown that the exposure to CQ, although it had no effect in the extracellular 
multiplication of R. equi, reduced significantly the viability of these bacteria inside 
murine and foal macrophages [37]. An explanation for these results relies on the fact 
that CQ is a weak base, which increases the pH of endocytic vesicles and lysosomes 
inside eukaryotic cells. Thus, it prevents the release of iron from those vesicles, which 
only happens when they have an acidic environment. Without iron, bacteria like R. equi 
or M. avium are deprived of one of their most essential nutrients and they are not able 
to survive [35, 37, 38]. 
 Primaquine (PQ) is the most effective and less toxic 8-aminoquinoline used as 
an antimalarial since the 1950s [39]. More recently, it was reported that primaquine at 5 
µM was able to inhibit the intracellular growth of Mtb [40], and some PQ-derivatives 
tested against Mtb, M. paratuberculosis and MAC showed strong antimycobacterial 
activity [41]. Therefore, PQ as well as CQ, are very interesting candidates for a new 
multi-targeted therapy. 
 
 
The chloroquine-cinnamoyl conjugates 
 
Paula Gomes’ research group has been working for years in the chemical 
recycling of classical antimalarial drugs, including CQ, with the purpose of finding new 
and innovative compounds that can be applied to the therapy of malaria. Issues like the 
emergence of new resistant strains and the lack of multi-stage treatments have led 
their investigation on the way to a “covalent bitherapy” approach. That is the creation of 
a hybrid molecule that conjugates two individual molecules with intrinsic activity that 
can enhance the potential of both parent drugs. The covalent linkage of the 
heteroaromatic ring of CQ to differently substituted cinnamoyl groups showed very 
promising results  against CQ-resistant Plasmodium falciparum [42] and as dual-stage 
antimalarial leads [43]. A study that evaluated the effect of the same N-cinnamoylated 
CQ conjugates against another parasite, Leishmania infantum, which infects 
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macrophages of mammalian hosts, obtained interesting results as well [44]. These 
conjugates were also recently tested against Pneumocystis jirovecii, an opportunistic 
fungus that infects patients with a compromised immune system [45].  
Given the promising results of these covalent compounds in terms of activity in 
vitro and the fact that they have effect in certain conditions that CQ by itself never 
showed having, our group decided to test them against M. avium in axenic cultures and 
when growing inside macrophages, as it is their main mammalian host.  
 
 
Characteristics and applications of ionic liquids 
 
A new approach has been developed to rescue old and less utilized drugs, as is 
the case of CQ, due to its unfavorable pharmacological properties, such as low 
solubility, spontaneous crystallization, high dosage needed to achieve the desirable 
effects or toxicity to the host infected cells. These difficulties can be overcome by the 
non-crystalline forms of those drugs, the ionic liquids (ILs), which are organic salts 
made by the combination of the active pharmaceutical ingredient, in its cationic or 
anionic form, and an inert counterion, or a counterion with additional biological interest. 
The cost of these procedure can even be lowered by, for example, combining classical 
drugs of opposed polarities [36, 46, 47].  
With remarkable physical and chemical properties, ILs were first used to 
improve the performance and safety of chemical procedures as green-solvents. Recent 
studies regarding the interaction between ILs and biomaterials have revealed their high 
potential to improve sensors and drug delivery systems [47]. It has been demonstrated 
that ILs work as well as antimicrobial agents, affecting several bacteria, including 
mycobacteria, and fungi [47]. The right combination of cations and anions can provide 
innovative compounds that help combat resistance issues.  
The combination of anionic ampicillin with organic cations resulted in ILs with 
activity against Gram-negative bacteria resistant to antibiotics [48]. ILs derived from a 
classical antimalarial drug, primaquine, an 8-aminoquinoline, were found to exhibit 
improved in vitro performances in comparison to primaquine and better in vitro 
activities than their covalent analogues [46]. ILs derived from N-cinnamoylated CQ 
conjugates were reported to have similar activity against Pneumocystis jirovecii than 
their covalent equivalents, however showed to be less cytotoxic to two different cell 
lines than those covalent equivalents [45].  
ILs mechanism of action is not yet fully understood. However, structural 
characteristics as the length of the cation side chain or the presence of polar functional 
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groups can alter properties such as lipophilicity and surface tension that are known to 
influence the activity of the compounds [47]. As active pharmaceutical ingredients, ILs 
emerge as a promising alternative for overcoming issues related to polymorphism while 
improving solubility and bioavailability in a cost-effective way.  
ILs are very promising in terms of efficacy, affordability and as a form of 
bypassing problems of resistance. Its properties allow the combination of conventional 
drugs with different effects but with a joined purpose. For example, a bacterial infection 
in an AIDS patient could be treated in the future with only one medicine, an IL formed 
by an anti-retroviral ion and a counterion with antibacterial activity.  
 
 
Objectives 
 
The objectives of this work were to: 
• Evaluate the susceptibility of different laboratory strains of M. avium to 
antibiotics conventionally used in the treatment of NTM infections; 
• Evaluate the capacity of CQ-derived ionic liquids to inhibit the viability and 
growth of M. avium 2447 SmT growing extracellularly and inside mouse 
macrophages. 
 
All the compounds tested were provided by Paula Gomes’ laboratory at 
LAQV/REQUIMTE, Faculdade de Ciências da Universidade do Porto, Portugal, unless 
stated otherwise.  
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Materials and methods 
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Compounds 
 
Conventional antibiotics  
 
 Table 1 shows the properties of the conventional antibiotics tested against 
different strains of M. avium.  
 
Table 1 – Properties of the conventional antibiotics. 
Name Chemical structure 
Molecular weight 
(g/mol) 
Azithromycin a 
 
785.02 
Rifampicin b 
 
822.94 
Streptomycin a 
 
 
728.69 
 Norfloxacin a 
 
319.34 
Ofloxacin a 
 
361.37 
 
a Acquired from Sigma-Aldrich. b Acquired from EDQM - European Directorate for the Quality of 
Medicines & Healthcare, Council of Europe.  
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CQ-cinnamic acid derivatives 
 
Table 2 and Table 3 show the properties of the CQ-cinnamic acid-derived ILs 
and covalent compounds, respectively, tested against M. avium 2447 SmT. CQ1 is the 
covalent equivalent of CQ1-IL, CQ2 is the covalent equivalent of CQ2-IL, CQ3 is the 
covalent equivalent of CQ3-IL and CQ4 is the covalent equivalent of CQ4-IL. 
 
Table 2 – Properties of the CQ-cinnamic acid-derived ionic liquids. 
 
Designation Chemical structure Molecular weight (g/mol) 
CQ1-IL 
 
 
441.91 
CQ2-IL 
 
441.98 
CQ3-IL 
 
429.92 
 CQ4-IL 
 
399.90 
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Table 3 – Properties of the CQ-cinnamic acid-derived covalent compounds. 
Designation Chemical structure Molecular weight (g/mol) clogP 
a 
CQ1 
 
 
393.92 4.68 
CQ2 
 
421.97 5.41 
CQ3 
 
409.91 4.01 
CQ4 
 
379.89 4.16 
 
a Calculated logarithm of the partition coefficient. Calculator Plugins were used for logP values 
prediction and calculation, Marvin 19.9.0, 2019, ChemAxon (http://www.chemaxon.com). 
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CQ/PQ-conventional antibiotic derivatives 
 
Table 4 shows the properties of the CQ/PQ-conventional antibiotics-derived ILs 
tested against M. avium 2447 SmT.  
 
Table 4 – Properties of the CQ/PQ-conventional antibiotics derivatives. 
Designation Chemical structure Molecular weight (g/mol) 
CQ5-IL 
 
 
681.20 
PQ1-IL 
 
898.03 
 
 
Bacteria 
 
M. avium 2447 smooth-transparent variant (SmT) was isolated from the bone 
marrow of an AIDS patient and was provided by Dr. Françoise Portaels (Institute of 
Tropical Medicine, Antwerp, Belgium). 
M. avium 25291 SmT was isolated from chicken and acquired from ATCC 
(American Type Culture Collection).  
M. avium 2-151 variants SmT and SmOp (smooth-opaque) were isolated from 
an AIDS patient and were provided by Dr. John Belisle (Colorado State University, 
Colorado, USA). 
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Axenic assay 
 
In order to assess the direct antimycobacterial activity of the compounds, the 
bacteria were grown in liquid culture medium and incubated with increasing 
concentrations of the different compounds. The viability of the mycobacteria was 
assessed through resazurin reduction and by Colony Forming Units (CFUs) assay.  
An axenic culture of M. avium was expanded in Middlebrook 7H9 medium (BD 
DifcoTM, Sparks, USA) supplemented with 10% of ADC (albumin-dextrose-catalase). 
The inoculum was incubated at 37ºC and the bacterial growth was monitored by 
measuring daily the optical density (OD) at 600 nm of the culture diluted 1:2 in medium. 
When the exponential phase was reached, the culture was diluted 1:10 in 7H9 
medium, with a final concentration of approximately 106 CFU/mL. 
In a 96-well plate, each compound was diluted successively 1:2 in 7H9/10% 
ADC. Then, mycobacterial culture was added 1:1 to each well, with a final volume of 
200 µL. Wells containing only medium and wells without treatment were also included. 
Each condition was tested in triplicates.  
The plate was incubated at 37ºC for six days. The antimycobacterial activity of 
the compounds was assessed by resazurin reduction. A solution of resazurin 
phosphate-buffered saline (PBS) 1× (2.5 mM) was prepared and 10% (v/v) was added 
to each well. After 24 hours of incubation at 37ºC, the fluorescence of resorufin, 
resulting from the conversion of resazurin by metabolically active cells, was measured 
at lex = 530 nm and lem = 590 nm in a SynergyTM Mx microplate reader using the 
software Gen5.  
From the results obtained by resazurin reduction, the value of IC50 
(concentration of the compound that inhibits by 50% the mycobacterial viability) was 
calculated for each condition. For that, GraphPad Prism 8 (GraphPad Software, LLC) 
software was used. The experimental values were subjected to a 4 parameters logistic 
sigmoidal regression and the values of IC50 were obtained by interpolation of the curve. 
On the seventh day of incubation, the viability of M. avium was also evaluated 
by colony forming units (CFUs) assay, using the same wells as the resazurin assay. 
The amount of bacteria incubated with the compounds was also determined by this 
method on day 0. The bacterial suspension in each well was serially diluted (1:10) in 
water containing 0.05% of Tween-80 and plated in Middlebrook 7H10 agar medium 
(BD DifcoTM, Sparks, USA) supplemented with 10% of oleic acid-albumin-dextrose-
catalase (OADC), for 7 days at 37ºC.  
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Bone marrow macrophages (BMM) 
 
 Macrophages were derived from the bone marrow of BALB/c or C57BL/6 mice 
bred at the i3S animal facility. Macrophages derived from the former strain of mice 
were used for experiments involving the CQ-cinnamic acid derivatives, while the 
macrophages derived from the latter strain of mice were used for experiments involving 
the CQ/PQ-conventional antibiotics derivatives and their parental antibiotics. Each 
strain was used according to momentary convenience; no differences are expected to 
result from the use of BMM from these two strains. 
The animal was euthanized by CO2 inhalation and its femurs and tibias 
removed. Each bone was flushed with Hank’s Balanced Salt Solution (HBSS, Gibco, 
Paisley, U.K.). The resulting cell suspension was centrifuged for 10 minutes at 259 g, 
4ºC, and re-suspended with Dulbecco’s Modified Eagle’s Medium (DMEM, Gibco, 
Paisley, U.K.) supplemented with 10 mM glutamine, 10 mM HEPES, 1 mM sodium 
pyruvate, 10% Fetal Bovine Serum (FBS, Biowest, France), and 10% of L929 cell 
conditioned medium (LCCM) as a source of Macrophage Colony Stimulating Factor (M-
CSF).  
Cells were cultured for at least 4 hours at 37ºC in a 7% CO2 atmosphere to 
remove fibroblasts. Non-adherent cells were collected and the plate was washed three 
times with cold HBSS. The cellular suspension was centrifuged at 259 g, 4ºC for 10 
minutes, re-suspended with DMEM and the number of cells counted using a Neubauer 
chamber. The cell concentration was adjusted to 4×105 cells/mL with supplemented 
DMEM/10% LCCM and the cell suspension was plated on 24-well plates (1 mL per 
well) or on 96-well plates (200 µL per well). 
The plates were incubated at 37ºC in a 7% CO2 atmosphere and, four days 
after seeding, 10% of LCCM was added to the culture medium. On the seventh day, 
the culture medium was renewed.  
On the day 10 of culture, the cells are considered fully differentiated into 
macrophages. The culture medium was removed and the adherent cells were 
incubated with a bacterial suspension of M. avium 2447 SmT at 106 CFU/mL, 
previously prepared in supplemented DMEM, for 4 hours at 37ºC in a 7% CO2 
atmosphere. After incubation, cells were washed four times with warm HBSS to 
remove non-internalized bacteria and re-incubated with new supplemented 
DMEM/10% LCCM with or without different concentrations of each compound. Each 
condition was tested in triplicates.  
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The viability of macrophages cultured in 96-well plates was determined by 
resazurin reduction. Four days after infection and treatment with compounds, a solution 
of resazurin in PBS 1× (1.25 mM) was prepared and 10% was added to each well. 
After 24 hours of incubation at 37ºC, the fluorescence of resorufin, resulting from the 
conversion of resazurin by metabolic active cells, was measured at lex = 530 nm and 
lem = 590 nm in a SynergyTM Mx microplate reader using the software Gen5. 
From the results obtained by resazurin reduction, the value of IC50 
(concentration of the compound that inhibits by 50% the macrophage viability) was 
calculated to each condition. For that, GraphPad Prism 8 (GraphPad Software, LLC) 
software was used. The experimental values were subjected to a 4 parameters logistic 
sigmoidal regression and the values of IC50 were obtained by interpolation of the curve. 
The intracellular growth of M. avium 2447 SmT was evaluated 5 days after 
infection, by CFUs assay. The macrophages in 24-well plates were lysed with 0.1% 
saponin. The bacterial suspension was serially diluted in water containing 0.05% of 
Tween-80 and plated in Middlebrook 7H10 agar medium supplemented with 10% of 
OADC. The number of colonies was counted after 7 days at 37ºC and compared with 
the number of colonies present at time zero. The difference, in terms of log10 CFU/mL 
between the last and the first day of incubation was designated “log increase”. 
 
 
Optical microscopy 
 
To evaluate the toxicity and the solubility of the compounds, 6 days after 
incubation, in the case of axenic assays, or after 4 days, in the case of BMM assays, 
images of bright field optical microscopy of each well were obtained using a Leica 
DMI6000 (Leica Microsystems, Germany) microscope and a Hamamatsu FLASH4.0 
(Hamamatsu, Japan) camera. The software used was LAS X. The equipment and 
software belonged to the Advanced Light Microscopy scientific platform at i3S.  
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Results 
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Effect of conventional antibiotics against M. avium 
 
 In order to understand the susceptibility of the M. avium strains we have in the 
laboratory to antibiotics that are currently used to treat NTM infections, we performed 
axenic assays with four different strains: M. avium 2447 SmT, M. avium 25291 SmT 
and M. avium 2-151 (variants SmOp and SmT). Each strain was incubated with 
increasing concentrations of three antibiotics: azithromycin, rifampicin and 
streptomycin, and the mycobacterial viability was assessed by resazurin reduction. The 
antimycobacterial effect of azithromycin was more accentuated against M. avium 2447 
SmT (Figure 4A) and 2-151 SmOp (Figure 4C) than against the other two strains.  
 
Figure 4 – Antimycobacterial activity of azithromycin. M. avium 2447 SmT (A), M. avium 25291 SmT (B), M. avium 
2-151 SmOp (C) or M. avium 2-151 SmT (D) was incubated with increasing concentrations of the antibiotic 
azithromycin, for 7 days at 37 °C. Mycobacterial viability was assessed through resazurin reduction. The graph shows 
the averages ± standard deviations of three (A) or two (B-D) independent experiments, presented as percentages of 
viable mycobacteria relative to the number of corresponding non-treated mycobacteria.  
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Rifampicin caused a significant decrease in the viability of M. avium 2447 SmT 
(Figure 5A) and the two variants of M. avium 2-151 (Figure 5C-D). However, against 
M. avium 25291 SmT (Figure 5B), this antibiotic does not seem to have an inhibitory 
effect.  
 
 
 
Figure 5 – Antimycobacterial activity of rifampicin. M. avium 2447 SmT (A), M. avium 25291 SmT (B), M. avium 2-
151 SmOp (C) or M. avium 2-151 SmT (D) was incubated with increasing concentrations of the antibiotic rifampicin, for 
7 days at 37 °C. Mycobacterial viability was assessed through resazurin reduction. The graph shows the averages ± 
standard deviations of three (A) or two (B-D) independent experiments, presented as percentages of viable 
mycobacteria relative to the number of corresponding non-treated mycobacteria.  
 
Streptomycin was more effective against the strains 2447 SmT (Figure 6A) and 
2-151 SmOp (Figure 6C). M. avium 25291 SmT was the strain less susceptible to this 
antibiotic, with its viability not decreasing below 60% at the higher concentration of the 
drug (100 µg/mL) (Figure 6B).  
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Figure 6 – Antimycobacterial activity of streptomycin. M. avium 2447 SmT (A), M. avium 25291 SmT (B), M. avium 
2-151 SmOp (C) or M. avium 2-151 SmT (D) were incubated with increasing concentrations of the antibiotic 
streptomycin, for 7 days at 37 °C. Mycobacterial viability was assessed through resazurin reduction. The graph shows 
the averages ± standard deviations of three (A) or two (B-D) independent experiments, presented as percentages of 
viable mycobacteria relative to the number of corresponding non-treated mycobacteria.  
 
Two additional conventional antibiotics, norfloxacin and ofloxacin, were tested 
against M. avium 2447 SmT (Figure 7). This strain was susceptible to both antibiotics, 
reducing the viability of the mycobacteria around 80% at the highest concentration 
tested.  
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Figure 7 – Antimycobacterial activity of norfloxacin and ofloxacin. M. avium 2447 SmT was incubated with 
increasing concentrations of the antibiotics norfloxacin (A) and ofloxacin (B) for 7 days at 37 °C. Mycobacterial viability 
was assessed through resazurin reduction. The graph shows the results of one experiment, presented as percentages 
of viable mycobacteria relative to the number of corresponding non-treated mycobacteria. 
 
Table 5 summarizes the activity of the antibiotics tested against the different 
strains of M. avium. For some cases it was not possible to calculate the IC50, as the 
inhibitory effect of the antibiotics was not significant at the highest concentration tested.  
 
Table 5 – Antimycobacterial activity of the antibiotics azithromycin, rifampicin, streptomycin, 
norfloxacin and ofloxacin against different strains of M. avium. 
 
 Activity a against different strains of M. avium 
Antibiotic 2447 SmT 25291 SmT 2-151 SmOp 2-151 SmT 
Azithromycin 4.17  (3.27) 
>127  
(100) 
10.92  
(8.57) 
>127  
(100) 
     
Rifampicin 1.50  (1.23)b 
>122  
(100) 
0.33  
(0.27) 
0.10  
(0.08)b 
     
Streptomycin 0.31  (0.24) 
>137  
(100) 
2.10  
(1.53) 
>137  
(100) 
     
Norfloxacin 4.10  (1.31)  - - - 
     
Ofloxacin 2.42  (0.87) - - - 
 
a IC50 (concentration of the compound that inhibits by 50% the mycobacterial viability) in µM (in 
parenthesis µg/mL); b R2<0.9 
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 All together, these results reveal a high variability in the susceptibility to 
conventional antibiotics amongst the various strains of M. avium. Strains like M. avium 
2447 SmT seem to be susceptible to all the antibiotics tested, but the same drugs do 
not look effective against M. avium 25291 SmT. Even between the same strain, as is 
the case of M. avium 2-151, different variants have different susceptibilities to the 
tested antibiotics.  
It is important to understand the behavior of these strains when looking for new 
alternatives to the established treatments to NTM infections. However, for the purpose 
of this thesis, we proceeded with the testing of new compounds on strain 2447 SmT. 
 
 
Effect of CQ-based ionic liquids on M. avium 2447 SmT 
 
Effect of CQ-cinnamic acid derivatives against axenic cultures of M. avium 
 
The fact that with the technology of ILs it is possible to conjugate CQ with other 
active molecules in the same drug, conserving both activities and at the same time 
bypassing pharmacological problems, caught our attention. Our first approach was to 
test ILs based on CQ, conjugated with differently substituted cinnamoyl groups. 
To test the direct antimycobacterial activity of the CQ-cinnamic acid-derived ILs 
and their respective covalent compounds we performed axenic assays. M. avium 2447 
SmT was incubated with increasing concentrations of each compound and the 
mycobacterial viability was assessed by resazurin reduction. Our results show that for 
most pairs of covalent-IL compounds, the covalent compound had higher direct 
inhibitory effect against M. avium than its equivalent ionic liquid (Figure 8A,B,C). The 
erratic behavior of the covalent compounds could be explained by their precipitation in 
contact with the culture medium, visible by optical microscopy (Figure 9). 
Nevertheless, we can conclude that all compounds, either covalent or ILs, do not show 
a significant activity against M. avium 2447 SmT, with viability not decreasing below 
60% for most of the cases. These results were confirmed by colony forming units 
(CFUs) assay (data not shown). 
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Figure 8 – Direct antimycobacterial activity of CQ-cinnamic acid derivatives. M. avium 2447 SmT was incubated 
with increasing concentrations of the covalent compounds (full line) CQ1 (A), CQ2 (B), CQ3 (C) or CQ4 (D) or its 
correspondent ionic liquids (dashed line) CQ1-IL (A), CQ2-IL (B), CQ3-IL (C) or CQ4-IL (D), for 7 days at 37 °C. 
Mycobacterial viability was assessed through resazurin reduction. The graph shows the averages ± standard deviations 
of four independent experiments, presented as percentages of viable mycobacteria relative to the number of 
corresponding non-treated mycobacteria.  
 
The images obtained by bright field optical microscopy show the precipitation of 
the covalent compounds in contact with the culture medium in contrast with what 
happens to the ILs (Figure 9). Over a layer of mycobacteria, the covalent compounds 
form different types of precipitates. In the images of the wells incubated with ILs, only 
the mycobacterial film is visible, even at concentrations four times higher than the 
covalent compounds.  
These results suggest that the CQ-cinnamic acid-derived ILs do not have an 
improved antimycobacterial activity, however are more soluble than the covalent 
compounds, which may be an important advantage. 
0 20 40 60 80 100
0
20
40
60
80
100
120
140
160
Concentration (µM)
%
 m
yc
ob
ac
te
ria
l v
ia
bi
lity
0 20 40 60 80 100
0
20
40
60
80
100
120
200
300
Concentration (µM)
%
 m
yc
ob
ac
te
ria
l v
ia
bi
lity
0 20 40 60 80 100
0
20
40
60
80
100
120
Concentration (µM)
%
 m
yc
ob
ac
te
ria
l v
ia
bi
lity
0 20 40 60 80 100
0
50
100
150
200
250
Concentration (µM)
%
 m
yc
ob
ac
te
ria
l v
ia
bi
lity
A B
C D
FCUP | ICBAS 
Evaluation of the effects of selected ionic liquids against Mycobacterium avium 
 41 
 
 
Figure 9 – Covalent compounds are less soluble than their equivalent ionic liquids. M. avium 2447 SmT was 
incubated with the covalent compounds CQ1 (A), CQ2 (B), CQ3 (C) or CQ4 (D) at 100 μM or its equivalent ionic liquids 
CQ1-IL (A), CQ2-IL (B), CQ3-IL (C) or CQ4-IL (D), at 100 or 400 μM. Representative brightfield images were acquired 
using a Leica DMI6000 (Leica Microsystems, Germany) microscope. Scale bar: 30 μm. 
 
 
Effect of CQ-cinnamic acid derivatives on M. avium-infected macrophages 
 
 Since the macrophage is one of the main host cells for M. avium upon infection, 
the next step was to test the CQ-cinnamic acid-derived compounds in a more relevant 
model. We performed in vitro assays with murine bone marrow derived macrophages 
(BMM) as a way to study the intramacrophagic antimycobacterial activity of the 
compounds. But, in first place, to evaluate the toxicity of the compounds to the host 
cells, BMM infected with M. avium 2447 SmT were incubated with increasing 
concentrations of each compound, and the toxicity was assessed by resazurin 
reduction (Figure 10). The macrophages in contact with the ILs are viable at higher 
concentrations than the macrophages in contact with each respective covalent 
A
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B
C
D
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compound. The pair CQ2/CQ2-IL (Figure 10B) presents the biggest difference in 
terms of toxicity to the macrophages between the two types of compounds.  
 
 
 
Figure 10 – Toxicity of CQ-cinnamic acid derivatives to host cells. BALB/c BMM infected with M. avium 2447 SmT 
were treated with increasing concentrations of the covalent compound (full line) CQ1 (A), CQ2 (B), CQ3 (C) or CQ4 (D) 
or its correspondent ionic liquid (dashed line) CQ1-IL (A), CQ2-IL (B), CQ3-IL (C) or CQ4-IL (D), for 5 days. 
Macrophage viability was assessed through resazurin reduction. The graph shows the averages ± standard deviations 
of three independent experiments, presented as percentages of viable macrophages relative to the number of 
corresponding non-treated macrophages.  
 
Similar assays were performed with non-infected BMM. Table 6 shows the 
calculated IC50 of each compound when in contact with infected or non-infected BMM. 
The non-infected macrophages seem to be more resistant to both ILs and covalent 
compounds than the infected macrophages. 
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Table 6 – Toxicity of the covalent compounds CQ1, CQ2, CQ3 and CQ4 and of the ionic liquids 
CQ1-IL, CQ2-IL, CQ3-IL and CQ4-IL against bone marrow derived macrophages (BMM). 
 
 Toxicity a of the compound to BMM 
Condition CQ1 CQ1-IL CQ2 CQ2-IL CQ3 CQ3-IL CQ4 CQ4-IL 
Infected 9.88 (3.89) 
23.07 
(10.19) 
4.84 
(2.04) 
28.90 
(12.77) 
16.00 
(6.56) 
24.83 
(10.67) 
13.24 
(5.03) 
27.23 
(10.89) 
         
Non-infected 13.96 (5.50)  
27.10 
(11.98) 
7.02 
(2.96) 
35.16 
(15.54) 
22.44 
(9.20) 
25.88 
(10.70) 
16.63 
(6.32) 
37.67 
(15.06) 
 
a IC50 (concentration of the compound that inhibits by 50% the macrophage viability) in µM (in 
parenthesis µg/mL). 
 
Images obtained by bright field optical microscopy show that the covalent 
compounds precipitate in contact with the culture medium at 100 µM, which does not 
happen with the ILs. Figure 11 shows representative images of infected BMM treated 
either with the covalent compound CQ2 or its equivalent ionic liquid CQ2-IL. At the 
higher concentration (100 µM) (Figure 11A), both compounds are toxic for the host 
cells, but the precipitate of the covalent compound is visible over the layer of dead 
macrophages, which does not happen with the IL. These images also confirm that the 
macrophages are viable at higher concentrations of the IL (18.75 µM) than of covalent 
compound (3.23 µM) (Figure 11B). This pattern is similar for the other 3 pairs of 
compounds (data not shown). 
 
Figure 11 – Ionic liquid CQ2-IL is more soluble and less toxic to BMM than the covalent compound CQ2. BALB/c 
BMM infected with M. avium 2447 SmT were incubated with the covalent compound CQ2 or its equivalent ionic liquid 
CQ2-IL at the highest concentration (100 μM) (A) or at the highest concentration where cells are viable, 3.23 μM for the 
covalent compound and 18.75 μM for the ionic liquid (B). Representative brightfield images were acquired using a Leica 
DMI6000 (Leica Microsystems, Germany) microscope. Scale bar: 30 μm. 
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To test the activity of these compounds against the bacteria inside the 
macrophages we performed CFUs assays. We evaluated the effect of the compounds 
at two concentrations that showed to be non-toxic to the macrophages. At the higher 
concentration the compounds were only administrated once, and at the lower 
concentration they were added every other day in a total of three administrations. We 
did not observe a significant inhibition of the mycobacterial growth by any of the 
compounds tested, IL or covalent (data not shown).  
These results suggest that the CQ-cinnamic acid-derived ILs have no activity 
against intramacrophagic M. avium, however they are less toxic and more soluble than 
their covalent equivalents. 
 
 
Effect of CQ/PQ-conventional antibiotics derivatives on M. avium viability in axenic 
culture 
 
 Since the CQ-cinnamic acid derivatives did not show the desired activity against 
M. avium, we decided to focus on ILs based on conventional molecules used to treat 
infections by NTM. We saw that depending on the strain, M. avium behaves differently 
to different antibiotics. M. avium 2447 SmT is a strain of intermediate virulence that 
showed to be susceptible to all the antibiotics tested (Figure 4-7).  
 As a first approach in this new phase, we tested the direct antimycobacterial 
activity of a CQ-conventional antibiotic-derived IL. This IL, CQ5-IL, is based on the 
molecule of ofloxacin. We also compared its activity with an IL based on the 
conjugation of another antimalarial, primaquine (PQ), and the antibiotic norfloxacin, 
denominated PQ1-IL.  
 We performed axenic assays in which M. avium 2447 SmT was incubated with 
increasing concentrations of each compound and the mycobacterial viability was 
assessed by resazurin reduction. Both PQ1-IL (Figure 12A) and CQ5-IL (Figure 12B) 
have a similar inhibitory effect on the viability of M. avium 2447 SmT. The IC50 
calculated for each IL was 2.08 µM (1.87 µg/mL) for PQ1-IL and 2.70 µM (1.84 µg/mL) 
for CQ5-IL. These results were confirmed by colony formation units (CFUs) assay (data 
not shown).  
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Figure 12 – Antimycobacterial activity of CQ/PQ-conventional antibiotics derivatives. M. avium 2447 SmT was 
incubated with increasing concentrations of the ionic liquids PQ1-IL (A) and CQ5-IL (B) for 7 days at 37 °C. 
Mycobacterial viability was assessed through resazurin reduction. The graph shows the averages ± standard deviations 
of four independent experiments, presented as percentages of viable mycobacteria relative to the number of 
corresponding non-treated mycobacteria.  
 
 The ILs based on conventional antibiotics present a better direct activity against 
M. avium than the CQ-cinnamic acid-derived ILs (Figure 8). Comparing with their 
parental antibiotics (Figure 7 and Table 5), the activity of CQ5-IL (IC50 = 2.70 µM) is 
very similar to the activity of ofloxacin (IC50 = 2.42 µM). PQ1-IL is slightly more active 
(IC50 = 2.08 µM) than norfloxacin (IC50 = 4.10 µM). Overall, in terms of extracellular 
action against M. avium, these ILs do not present an advantage compared to the 
already clinically approved compounds. 
 
 
Effect of CQ-conventional antibiotics derivatives on M. avium-infected macrophages 
 
To test the toxicity of the CQ/PQ-conventional antibiotic-derived ILs for the host 
cell and evaluate the intramacrophagic antimycobacterial activity of the compounds, we 
performed in vitro assays with infection of BMM with M. avium 2447 SmT. In order to 
compare the ILs with their parental drugs we also tested the toxicity and 
intramacrophagic activity of the antibiotics norfloxacin and ofloxacin.  Figure 13 
presents the toxicity of PQ1-IL (IC50 = 15.74 µM) (Figure 13A) and CQ5-IL (IC50 = 
20.65 µM) (Figure 13B) to the host cells. Both parental antibiotics were not toxic to the 
macrophages at any concentration tested (1 to 100 µM) (data not shown). 
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Figure 13 – Toxicity of CQ/PQ-conventional antibiotic-derived ILs to host cells. C57BL/6 BMM infected with M. 
avium 2447 SmT were treated with increasing concentrations of the ionic liquids PQ1-IL (A) and CQ5-IL (B), for 5 days. 
Macrophage viability was assessed through resazurin reduction. The graph shows the averages ± standard deviations 
of three independent experiments, presented as percentages of viable macrophages relative to the number of 
corresponding non-treated macrophages.  
 
To test the activity of these compounds against the bacteria inside the 
macrophages we performed CFUs assays. We evaluated the effect of the compounds 
at three concentrations that showed to be non-toxic to the macrophages (Figure 14). 
The ILs seem to be more active than the parental antibiotics. At the concentrations 
tested, the fluoroquinolones do not show significant activity against the intracellular 
growth of M. avium. However, as they are not cytotoxic, higher concentrations may be 
more effective without causing damage to the host cells. At the same time, these 
results suggest that by opting for the ILs instead of the conventional antibiotics, it can 
be possible to reduce the concentration administered.  
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Figure 14 – Intramacrophagic activity of CQ/PQ-conventional antibiotic-derived ILs and their parental 
antibiotics. C57BL/6 BMM infected with M. avium 2447 SmT were treated with 4, 8 and 10 µM of PQ1-IL, CQ5-IL, 
norfloxacin (NOR) or ofloxacin (OFLO), for 5 days. The intramacrophagic bacterial loads were quantified by CFUs 
assay. The graph shows the averages ± standard deviations of two independent experiments, presented as the 
difference, in terms of log10 CFU/mL between day 5 and day 0 of incubation (log increase). 
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Discussion 
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 One of the main issues of trying to find new solutions to treat M. avium related 
diseases is the great variability of susceptibilities that each strain has to the treatments. 
We tested five antibiotics that are currently used in the clinic against three different 
strains of M. avium and the results could not be more diverse. Azithromycin, a 
macrolide that is the base of the treatment of infections by slow-growing NTM [12], was 
able to significantly inhibit the viability of two strains of intermediate virulence, M. avium 
2447 SmT and M. avium 2-151 SmOp [14]. However, its effect against M. avium 25291 
SmT, a strain of higher virulence [14], was much more modest. The IC50 of 
azithromycin, the concentration that inhibits 50% of the mycobacterial viability, was 
3.27 µg/mL for M. avium 2447 SmT and 8.57 µg/mL for M. avium 2-151 SmOp, which 
are consistent with reported values for MAC isolates [49]. 
Rifampicin is an antibiotic that was added to the regimen when the problem of 
macrolide-resistance emerged [27]. Together with a macrolide and ethambutol, the 
three constitute the recommended MAC therapy [29]. We observed that, like what 
happened with the macrolide, the M. avium strains of intermediate virulence, 2447 
SmT and the two variants of 2-151, were susceptible to rifampicin, but the same was 
not visible for M. avium 25291 SmT. This strain seemed even to increase its viability in 
the presence of the antibiotic. However, what seems an increase in viability could only 
mean that the bacteria were experiencing a faster metabolism, as cells metabolically 
more active reduce more resazurin. Heifets [50] tested the susceptibility of several M. 
avium strains and found that the majority (70.9%) were moderately susceptible to 
rifampicin, with a MIC varying between 1 and 4 µg/mL. Our IC50 value for M. avium 
2447 SmT (1.23 µg/mL) fits in that interval. The IC50 for M. avium 2-151 SmOp (0.27 
µg/mL) fits in the “susceptible” category of that study (MIC ≤ 0.5 µg/mL), like 19.4% of 
the MAC strains studied.  
In more severe or specific cases of MAC disease, a fourth antibiotic is often 
added to the treatment, as is the case of aminoglycosides like streptomycin [30]. In this 
work, this antibiotic seems to be more active against M. avium 2447 SmT and M. avium 
2-151 SmOp than against M. avium 25291 SmT and M. avium 2-151 SmT. Heifets later 
assessed the susceptibility of M. avium strains, isolated from patients with or without 
AIDS, to injectable antibiotics like streptomycin [51], concluding that the majority of 
isolates from both groups of patients fitted between a MIC range of 4 to 6 µg/mL. Our 
M. avium 2447 SmT and M. avium 2-151 SmOp seem to be more susceptible to 
streptomycin, as the IC50 for both strains is lower than 2 µg/mL. 
We additionally tested two fluoroquinolones, norfloxacin and ofloxacin, against 
M. avium 2447 SmT. Like the aminoglycosides, fluoroquinolones are sometimes joined 
to the treatment in cases of severe and resistant MAC disease [27]. It was not possible 
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to test these fluoroquinolones against the other strains of M. avium, however we can 
observe that M. avium 2447 SmT was susceptible to these antibiotics in a 
concentration-depending way, similarly to what happened with the other antibiotics. 
The IC50 that we obtained for ofloxacin was 1.61 µg/mL, which is lower than the IC50 
determined by Vacher et al. against 41 MAC isolates (8 µg/mL) [52]. In our work, 
norfloxacin also seems to be more active (IC50 = 2.17 µg/mL) than Gay et al. reported 
against 20 MAC isolates (IC50 = 16 µg/mL) [53]. 
Altogether, these results confirm the different behavior of each strain of M. 
avium in the presence of the same antibiotic. This work must be optimized, testing 
more clinically approved antibiotics and evaluating the strain’s susceptibility using more 
accurate methods, like CFUs assays. The great variability of susceptibilities inside the 
same species is a factor that challenges the research with M. avium, as all the different 
strains must be taken into account to have a better representation of the population. 
We can infer from our results that a regimen of mono-therapy would not be the most 
effective, and thus, not recommended. A combined therapy of antibiotics with different 
mechanisms of action, besides avoiding the development of resistances, increases the 
probability of success of the treatment, mainly when the strain is not previously 
identified. Establishing a method of diagnosis including the identification of the strain 
before the patient starts the therapy would be very useful and important to ensure the 
success of the treatment.  
It was important for us to have a general idea of the susceptibility of M. avium to 
conventional antibiotics, to help identify interesting and relevant structures that can be 
applied in new compounds with potential action against M. avium. The strategy of 
using ionic liquids to overcome problems of solubility or toxicity to the host cells and, at 
the same time, improve the activity of the original drugs [47] is very promising and 
tempting.   
We started by testing ILs that were synthetized having as base the molecule of 
CQ. The multi-versed properties of CQ, an antimalarial with activity against HIV, that 
has also an inhibitory effect in the viability of M. avium [35], brought interest to this 
molecule when considering a new strategy to combinatory therapies. The covalent 
conjugation of CQ with differently substituted cinnamoyl groups enhanced the activity 
of CQ against different parasites [43-45]. Therefore, it was interesting to test these 
compounds against M. avium and, at the same time, evaluate their activity in the form 
of IL. It was visible that M. avium 2447 SmT was a strain very consistent in its 
susceptibility to all the antibiotics tested. We decided, then, to test the new compounds 
against this strain of M. avium.  
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In terms of direct activity against M. avium, we observed that the ILs present a 
low inhibitory effect, which did not allow us to calculate their IC50. The covalent 
compounds present a very erratic behavior. We confirmed by optical microscopy that 
the covalent compounds precipitate in contact with the culture medium, which could 
interfere with the fluorescence measure. Thus, for the covalent compounds, this 
quantification may not translate the real viability of the bacteria. The ILs had a much 
more constant behavior, as they do not precipitate in contact with the culture medium 
even when four times more concentrated than the covalent compounds. Thus, we can 
conclude that the CQ-cinnamic acid-derived ILs are not more active against M. avium 
than their covalent equivalents, however they are more soluble, which confirms the 
ability of these compounds to overcome pharmacological issues of their drugs of origin.  
Next, it was important to evaluate the effect of the CQ-cinnamic acid derivatives 
against M. avium inside their host cells, the macrophages. One important factor in the 
development of new compounds is the selectivity towards the pathogen of interest, 
meaning, they should have a high antimicrobial activity, while at the same time not 
being toxic for the host. Comparing the toxicity of the ILs with the covalent compounds, 
we can see that all the ILs are cytotoxic at higher concentrations than the respective 
covalent compound. Again, by optical microscopy it is possible to observe that the 
covalent compounds precipitate, which does not happen with the ILs. Regarding their 
intramacrophagic antimicrobial activity, none of the compounds, covalent or ionic liquid, 
showed a significant inhibition of the mycobacterial growth, even when administered 
more than once. Thus, the ILs are more soluble and less toxic to the macrophages, 
however they are not more active than the equivalent covalent compounds.  
These CQ-cinnamic acid-derived ILs have not yet been tested against any 
microorganism, so it is not possible to compare our results with results previously 
described in literature. Some of their covalent equivalents have been tested against 
two parasites, Plasmodium falciparum [42, 43], that causes malaria, and Leishmania 
infantum [44], and the fungus Pneumocystis jirovecii [45]. The life cycle of the malaria 
parasite inside a human host comprises two different stages: a silent liver stage with no 
manifestation of disease and a clinically symptomatic blood stage with invasion of 
erythrocytes [54]. CQ is only active against the blood-stage malaria. However, when 
studying these compounds against P. falciparum, it was visible that CQ-cinnamic acid 
conjugates display high in vitro potency against both blood and liver stage parasites 
and showed actually higher activity in vitro against erythrocytic parasites than CQ itself 
[42, 43]. The performance of these covalent compounds against the malaria parasite in 
vivo was more modest and some of them were highly toxic to the infected mice [43]. 
The high lipophilicity (logP values around 5, see Table 3) of these compounds can 
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explain those issues, as this factor is related to extensive binding to plasma proteins 
and to accumulation in cellular membranes with concomitant damage. Actually, from 
the compounds that we tested, CQ2 was the most toxic to mice in that study. In our 
work, CQ2 was also the covalent compound with higher toxicity to BMM. Contributing 
to the toxicity of CQ2 are a great number of hydrophobic chemical groups (Table 3), 
which makes this the compound with highest logP (5.41). On the other hand, CQ3 was 
considered the compound with better “druglikeness” of the study, as it had a high 
activity and low toxicity in vivo. Again, CQ3 was also the covalent compound with lower 
toxicity to BMM, although it does not show activity against M. avium in vitro.  
Against Leishmania infantum, although none of the CQ-cinnamic acid-derived 
covalent compounds showed better activity than CQ against promastigotes (the form 
that infects the insect), they all performed better than CQ against amastigotes, which is 
the intramacrophagic form of the parasite [44]. The authors speculate that CQ is more 
easily expelled from the amastigote than the cinnamic acid conjugates through 
species-specific transporters; however, they confirmed by resazurin reduction assay 
that these conjugates are more cytotoxic to the host cells, and in consequence to the 
parasite, than CQ, explaining their higher activity. CQ2 was again the most toxic 
compound to BMM and CQ3 was one of the most active and less cytotoxic compounds 
[44].  
A recent study evaluated the effect of some of the CQ-cinnamic acid-derived 
covalent compounds against the fungus Pneumocystis jirovecii. The compounds 
showed similar or improved activity than CQ (CQ1 and CQ3 had the higher activities) 
and most of them did not show cytotoxicity against the mammalian cell lines A549 and 
L2, with the exception of CQ2 [45]. They also tested the activity of two CQ-cinnamic 
acid-derived ILs against the fungus, however they were not the same ones as we 
tested. Nevertheless, those ILs had a similar activity than their covalent counterparts 
but were much less cytotoxic. Our results also suggest the same relation between ILs 
and covalent compounds.  
The fact that these CQ-cinnamic acid derivatives can effectively inhibit the 
growth of two parasites with a similar life cycle and an intramacrophagic fungus, but 
are not active against intracellular bacteria like M. avium, given that all of these 
microorganisms were more or less susceptible to CQ, suggests that a chemical 
alteration in the synthesis of these conjugates could have changed the mechanism of 
action of CQ. Also, the addition of a cinnamoyl group that turned the CQ-based 
compound in a drug with effect against both stages of P. falciparum, might have 
“hidden” a chemical group that was essential for the activity of CQ against M. avium. In 
fact, it has been reported [55] that the tertiary amine in the aliphatic chain of CQ 
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(Figure 3) is a key factor for the activity of CQ, given the basicity that this chemical 
group confers. Although afterwards it has been proved that that tertiary amine is not so 
important, because the CQ-cinnamic acid conjugates have effect against the malaria 
parasite without it [42, 43], that group could still be important for the activity against 
mycobacteria. Gressler et al. [37] suggested that the weak basicity of CQ is essential 
for altering the pH of iron containing vesicles, preventing the release of this nutrient into 
the cell and depriving the bacteria from it, which could be crucial for the 
antimycobacterial activity of CQ. 
 The CQ-cinnamic acid-derived compounds did not show direct or 
intramacrophagic activity against M. avium. But the results we obtained with the ILs 
were promising in terms of bypassing pharmacologic issues such as solubility or 
toxicity to the host cells. So, we kept the research in the line of the ILs but focusing in 
new combinations that could be more favorable. In the first part of the work we saw 
that there is a great variability in the susceptibility of different strains of M. avium to 
conventional antibiotics. Norfloxacin and ofloxacin have a simpler structure than the 
other conventional antibiotics, which makes them more appealing in a first phase for 
the synthesis of new ILs. They were conjugated with CQ and PQ having in mind their 
described activity against M. avium [35, 41] and because of the ambition of finding a 
compound that could work in a combinatory therapy for concomitant diseases. CQ was 
thus combined with ofloxacin and PQ was combined with norfloxacin. Both CQ/PQ-
conventional-derived ILs had a direct inhibitory effect against M. avium. While these 
results are very encouraging, as these new ILs have a much more accentuated effect 
than the previously tested ILs, we must consider the effect of their parental drugs. The 
IC50 of ofloxacin was 2.42 µM, whereas the IC50 of CQ5-IL, the IL based on the 
molecule of ofloxacin, was 2.70 µM. The fluoroquinolones were only tested once, thus 
no straightforward conclusions can be taken, but all indicates that the activity of the two 
compounds is very similar. PQ1-IL, the IL based on the molecule of norfloxacin, had an 
IC50 of 2.08 µM and norfloxacin had an IC50 of 4.10 µM. At first glance, the IL seems to 
be twice as active as the conventional antibiotic. But, as can be seen in Table 4, PQ1-
IL was not synthetized equimolarly, as it has 2 molecules of norfloxacin to 1 one of PQ, 
which could explain the doubled activity of the IL in relation to the parental drug.  
The direct activity of these CQ/PQ-conventional-derived ILs in comparison to 
the CQ-cinnamic acid-derived ILs against M. avium is, on the other hand, very 
significant. If we do not consider that the strength of the compound is all placed in the 
fluoroquinolone, we can speculate that the former follow a much more advantageous 
mechanism of action, interacting with targets linked to a better antimycobacterial effect.  
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It was, however, important to test the CQ/PQ-conventional-derived ILs in a 
more relevant model. In contact with infected macrophages, the ILs showed to be more 
toxic than norfloxacin and ofloxacin. Neither of the fluoroquinolones caused 
macrophage death at the higher concentration tested (100 µM), but the ILs were toxic 
above 15 to 20 µM. The fact that these ILs are heavier molecules constituted by 
several heterocyclic aromatic groups from both the anionic and cationic parts could 
explain the higher cytotoxicity comparing with the parental antibiotics. Nevertheless, 
the intramacrophagic activity of the ILs is higher than the activity of the 
fluoroquinolones. This is a very important factor, as it indicates that this new 
formulation could be of interest for future developments.  
The conjugation of fluoroquinolones with CQ in the form of IL is just the first 
step towards the development of new drugs with the potential to be used against more 
than one pathogen and, at the same time, be a solution to the emergent problem that is 
the resistance to antibiotics. In the future, our aim is to optimize the syntheses in order 
to conjugate more complex molecules, like first line NTM antibiotics, with other active 
pharmacophores. With those ILs we expect to enhance or at least maintain the activity 
of their parental drugs, and to improve pharmacological issues that excluded them from 
the current accepted therapies. Rescuing cheap and safe old drugs is one of the 
solutions to overcome the scarcity of effective antibiotics and combat the increase in 
the incidence of some diseases that affect millions of people per year. 
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